{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:35:02Z","timestamp":1782844502233,"version":"3.54.5"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100015854","name":"Scott R. MacKenzie Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015854","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010806","name":"Amgen Nederland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010806","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.ijcard.2020.11.042","type":"journal-article","created":{"date-parts":[[2020,11,23]],"date-time":"2020-11-23T11:31:52Z","timestamp":1606131112000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI"],"prefix":"10.1016","volume":"328","author":[{"given":"Anne H.","family":"Tavenier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renicus S.","family":"Hermanides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominick J.","family":"Angiolillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnoud W.J.","family":"van 't Hof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.ijcard.2020.11.042_bb0005","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1056\/NEJMoa1908973","article-title":"Ticagrelor or Prasugrel in patients with acute coronary syndromes","volume":"381","author":"Sch\u00fcpke","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2020.11.042_bb0010","doi-asserted-by":"crossref","first-page":"e362","DOI":"10.1161\/CIR.0b013e3182742c84","article-title":"2013 ACCF\/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation\/American Heart Association task force on practice guidelines","volume":"127","author":"O\u2019Gara","year":"2013","journal-title":"Circulation."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurheartj\/ehx393","volume":"39","author":"Ibanez","year":"2018","journal-title":"Eur. Heart J."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.042_bb0020","first-page":"352","article-title":"Comparative review of oral P2Y(12) inhibitors","volume":"43","author":"Koski","year":"2018","journal-title":"P T"},{"issue":"1","key":"10.1016\/j.ijcard.2020.11.042_bb0025","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5551\/jat.48934","article-title":"Association between high platelet reactivity following dual antiplatelet therapy and ischemic events in Japanese patients with coronary artery disease undergoing stent implantation","volume":"27","author":"Nishikawa","year":"2020","journal-title":"J. Atheroscler. Thromb."},{"issue":"16","key":"10.1016\/j.ijcard.2020.11.042_bb0030","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1016\/j.jcin.2019.03.034","article-title":"Updated expert consensus statement on platelet function and genetic testing for guiding P2Y12 receptor inhibitor treatment in percutaneous coronary intervention","volume":"12","author":"Sibbing","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0035","first-page":"331","article-title":"The relationship between platelet reactivity and infarct-related artery patency in patients presenting with a ST-elevation myocardial infarction","volume":"106","author":"Breet","year":"2011","journal-title":"Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.042_bb0040","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJMoa1407024","article-title":"Prehospital ticagrelor in ST-segment elevation myocardial infarction","volume":"371","author":"Montalescot","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ijcard.2020.11.042_bb0045","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.jcin.2015.12.024","article-title":"Effect of pre-hospital Ticagrelor during the first 24 h after primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction: the ATLANTIC-H24 analysis","volume":"9","author":"Montalescot","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"issue":"1","key":"10.1016\/j.ijcard.2020.11.042_bb0050","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4244\/EIJ-D-16-00965","article-title":"Impact of presentation and transfer delays on complete ST-segment resolution before primary percutaneous coronary intervention: insights from the ATLANTIC trial","volume":"13","author":"Fabris","year":"2017","journal-title":"EuroIntervention."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0055","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/1074248419882923","article-title":"What are optimal P2Y12 inhibitor and schedule of administration in patients with acute coronary syndrome?","volume":"25","author":"Cohen","year":"2020","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.ijcard.2020.11.042_bb0060","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jacc.2014.08.056","article-title":"Ticagrelor crushed tablets administration in STEMI patients: the MOJITO study","volume":"65","author":"Parodi","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"17","key":"10.1016\/j.ijcard.2020.11.042_bb0065","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.jacc.2016.02.045","article-title":"Crushed Prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study","volume":"67","author":"Rollini","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2020.11.042_bb0070","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCULATIONAHA.120.051532","article-title":"Effect of crushed prasugrel tablets in patients with STEMI planned for percutaneous coronary intervention: the randomized COMPARE CRUSH trial","author":"Vlachojannis","year":"2020","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2020.11.042_bb0075","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.thromres.2016.10.013","article-title":"Chewed ticagrelor tablets provide faster platelet inhibition compared to integral tablets: the inhibition of platelet aggregation after administration of three different ticagrelor formulations (IPAAD-Tica) study, a randomised controlled trial","volume":"149","author":"Venetsanos","year":"2017","journal-title":"Thromb. Res."},{"issue":"4","key":"10.1016\/j.ijcard.2020.11.042_bb0080","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1160\/TH16-09-0728","article-title":"Chewing versus swallowing Ticagrelor to accelerate platelet inhibition in acute coronary syndrome - the CHEERS study. For the PLATIS (platelets and thrombosis in Sheba) study group","volume":"117","author":"Asher","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.042_bb0085","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/jth.14434","article-title":"Efficacy and safety of alternative oral administrations of P2Y12-receptor inhibitors: systematic review and meta-analysis","volume":"17","author":"Serenelli","year":"2019","journal-title":"J. Thromb. Haemost."},{"issue":"11","key":"10.1016\/j.ijcard.2020.11.042_bb0090","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.jcin.2015.02.030","volume":"8","author":"Franchi","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"issue":"10","key":"10.1016\/j.ijcard.2020.11.042_bb0095","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jacc.2013.05.021","article-title":"Double versus standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI","volume":"62","author":"Alexopoulos","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.042_bb0100","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.ahj.2014.03.011","article-title":"Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: the rapid activity of platelet inhibitor drugs (RAPID) primary PCI 2 study","volume":"167","author":"Parodi","year":"2014","journal-title":"Am. Heart J."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0105","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/CIRCINTERVENTIONS.113.001118","article-title":"Onset of antiplatelet action with high (100 mg) versus standard (60 mg) loading dose of prasugrel in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: pharmacodynamic study","volume":"7","author":"Alexopoulos","year":"2014","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"14","key":"10.1016\/j.ijcard.2020.11.042_bb0110","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of platelet inhibition with cangrelor during PCI on ischemic events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcard.2020.11.042_bb0115","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11239-012-0737-3","article-title":"Pharmacodynamic effects of cangrelor and clopidogrel: the platelet function substudy from the cangrelor versus standard therapy to achieve optimal management of platelet inhibition (CHAMPION) trials","volume":"34","author":"Angiolillo","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"issue":"9909","key":"10.1016\/j.ijcard.2020.11.042_bb0120","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet."},{"issue":"14","key":"10.1016\/j.ijcard.2020.11.042_bb0125","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.ijcard.2020.11.042_bb0130","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1080\/09537104.2016.1246714","article-title":"Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction","volume":"28","author":"Mohammad","year":"2017","journal-title":"Platelets."},{"issue":"20","key":"10.1016\/j.ijcard.2020.11.042_bb0135","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1161\/CIRCULATIONAHA.117.031164","article-title":"International expert consensus on switching platelet P2Y(12) receptor-inhibiting therapies","volume":"136","author":"Angiolillo","year":"2017","journal-title":"Circulation."},{"issue":"4","key":"10.1016\/j.ijcard.2020.11.042_bb0140","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","article-title":"Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect","volume":"121","author":"Steinhubl","year":"2008","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0145","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jcin.2016.10.004","article-title":"Randomized comparison of Oral P2Y12-receptor inhibitor loading strategies for transitioning from Cangrelor: the ExcelsiorLOAD2 trial","volume":"10","author":"Hochholzer","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"10.1016\/j.ijcard.2020.11.042_bb0150","doi-asserted-by":"crossref","DOI":"10.1177\/1753944719893274","article-title":"Intravenous antiplatelet therapies (glycoprotein IIb\/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use","volume":"13","author":"Capodanno","year":"2019","journal-title":"Ther. Adv. Cardiovasc. Dis."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0155","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/hrt.2010.194951","article-title":"High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the on-TIME 2 trial","volume":"97","author":"Hermanides","year":"2011","journal-title":"Heart."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.042_bb0160","first-page":"956","article-title":"The effect of pre-hospital glycoprotein IIb-IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI","volume":"79","author":"Hermanides","year":"2012","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"10","key":"10.1016\/j.ijcard.2020.11.042_bb0165","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1111\/j.1538-7836.2009.03573.x","article-title":"Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction","volume":"7","author":"Heestermans","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"19","key":"10.1016\/j.ijcard.2020.11.042_bb0170","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1136\/heartjnl-2017-311181","article-title":"Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction","volume":"103","author":"Fabris","year":"2017","journal-title":"Heart."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0175","first-page":"335","volume":"74","author":"Hassan","year":"2009","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"14","key":"10.1016\/j.ijcard.2020.11.042_bb0180","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/eurheartj\/ehq143","article-title":"Use of glycoprotein IIb\/IIIa inhibitors in primary percutaneous coronary intervention: insights from the APEX-AMI trial","volume":"31","author":"Huber","year":"2010","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2020.11.042_bb0185","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/eurheartj\/ehl472","article-title":"Abciximab in primary coronary stenting of ST-elevation myocardial infarction: a European meta-analysis on individual patients\u2019 data with long-term follow-up","volume":"28","author":"Montalescot","year":"2007","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2020.11.042_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jacc.2014.10.029","article-title":"Bivalirudin versus heparin with or without glycoprotein IIb\/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials","volume":"65","author":"Stone","year":"2015","journal-title":"J. Am. Coll. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcard.2020.11.042_bb0195","first-page":"E204","article-title":"Glycoprotein IIb\/IIIa inhibitor use in patients with acute myocardial infarction undergoing PCI: insights from the TRANSLATE ACS study","volume":"93","author":"Ibrahim","year":"2019","journal-title":"Catheter. Cardiovasc. Interv."},{"issue":"1","key":"10.1016\/j.ijcard.2020.11.042_bb0200","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1055\/s-0039-1700546","article-title":"Efficacy and safety of glycoprotein IIb\/IIIa inhibitors on top of Ticagrelor in STEMI: a subanalysis of the ATLANTIC trial","volume":"120","author":"Tavenier","year":"2020","journal-title":"Thromb. Haemost."},{"issue":"3","key":"10.1016\/j.ijcard.2020.11.042_bb0205","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.jcin.2012.01.006","volume":"5","author":"Valgimigli","year":"2012","journal-title":"JACC Cardiovasc. Interv."},{"issue":"25","key":"10.1016\/j.ijcard.2020.11.042_bb0210","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJM200106213442503","article-title":"Platelet glycoprotein IIb\/IIIa inhibition with coronary stenting for acute myocardial infarction","volume":"344","author":"Montalescot","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2020.11.042_bb0215","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1161\/CIRCULATIONAHA.120.046928","article-title":"Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment\u2013elevation myocardial infarction - primary results of the FABOLUS-FASTER trial","volume":"142","author":"Gargiulo","year":"2020","journal-title":"Circulation."},{"issue":"3","key":"10.1016\/j.ijcard.2020.11.042_bb0220","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1093\/eurheartj\/ehv547","article-title":"Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial","volume":"37","author":"Kubica","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2020.11.042_bb0225","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ahj.2016.04.004","article-title":"The on- and off-target effects of morphine in acute coronary syndrome: a narrative review","volume":"176","author":"McCarthy","year":"2016","journal-title":"Am. Heart J."},{"issue":"1","key":"10.1016\/j.ijcard.2020.11.042_bb0230","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.114.001593","article-title":"Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention","volume":"8","author":"Parodi","year":"2014","journal-title":"Circ. Cardiovasc. Interv."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0235","first-page":"369","article-title":"P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. The PRIVATE-ATLANTIC study","volume":"116","author":"Silvain","year":"2016","journal-title":"Thromb. Haemost."},{"issue":"2","key":"10.1016\/j.ijcard.2020.11.042_bb0240","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s40256-018-0305-0","article-title":"Morphine and Ticagrelor interaction in primary percutaneous coronary intervention in ST-segment elevation myocardial infarction: ATLANTIC-morphine","volume":"19","author":"Lapostolle","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"3","key":"10.1016\/j.ijcard.2020.11.042_bb0245","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1055\/s-0038-1629896","article-title":"Morphine analgesia pre-PPCI is associated with Prothrombotic state, reduced spontaneous reperfusion and greater infarct size","volume":"118","author":"Farag","year":"2018","journal-title":"Thromb. Haemost."},{"issue":"13","key":"10.1016\/j.ijcard.2020.11.042_bb0250","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/eurheartj\/ehv567","volume":"37","author":"Puymirat","year":"2016","journal-title":"Eur. Heart J."},{"issue":"3","key":"10.1016\/j.ijcard.2020.11.042_bb0255","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1161\/CIRCULATIONAHA.117.031678","article-title":"Effect of intravenous fentanyl on Ticagrelor absorption and platelet inhibition among patients undergoing percutaneous coronary intervention: the PACIFY randomized clinical trial (platelet aggregation with Ticagrelor inhibition and fentanyl)","volume":"137","author":"McEvoy","year":"2018","journal-title":"Circulation."},{"issue":"16","key":"10.1016\/j.ijcard.2020.11.042_bb0260","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.jcin.2019.05.028","article-title":"Effects of methylnaltrexone on ticagrelor-induced antiplatelet effects in coronary artery disease patients treated with morphine","volume":"12","author":"Franchi","year":"2019","journal-title":"JACC Cardiovasc. Interv."},{"issue":"12","key":"10.1016\/j.ijcard.2020.11.042_bb0265","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1055\/s-0038-1675605","article-title":"METoclopramide administration as a strategy to overcome MORPHine-ticagrelOr interaction in PatientS with unstable angina PectorIS-the METAMORPHOSIS trial","volume":"118","author":"Sikora","year":"2018","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2020.11.042_bb0270","article-title":"Impact of opioids on P2Y12-receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial","author":"Tavenier","year":"2020","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"issue":"6","key":"10.1016\/j.ijcard.2020.11.042_bb0275","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1080\/13543784.2020.1764533","article-title":"Selatogrel, a novel P2Y(12) inhibitor: a review of the pharmacology and clinical development","volume":"29","author":"Milluzzo","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"33","key":"10.1016\/j.ijcard.2020.11.042_bb0280","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/eurheartj\/ehz807","article-title":"Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes","volume":"41","author":"Storey","year":"2020","journal-title":"Eur. Heart J."},{"issue":"20","key":"10.1016\/j.ijcard.2020.11.042_bb0285","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1016\/j.jacc.2020.03.059","article-title":"Subcutaneous Selatogrel inhibits platelet aggregation in patients with acute myocardial infarction","volume":"75","author":"Sinnaeve","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2020.11.042_bb0290","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1161\/ATVBAHA.114.303724","article-title":"RUC-4: a novel \u03b1IIb\u03b23 antagonist for prehospital therapy of myocardial infarction","volume":"34","author":"Li","year":"2014","journal-title":"Arterioscler. Thromb. Vasc. Biol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320341656?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527320341656?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:51:03Z","timestamp":1759092663000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527320341656"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":58,"alternative-id":["S0167527320341656"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.11.042","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bridging the gap: Current and future insights for improving suboptimal platelet inhibition in STEMI","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2020.11.042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}